CD44 and prostate small cell carcinoma: Furthermore, overexpression of CD44 enhances glycolytic activity in the highly aggressive prostate small cell neuroendocrine carcinoma (SCNC) via PFKFB4 upregulation, whereas knockdown of CD44 by RNA interference increases the sensitivity of SCNC cells to carboplatin (208).